



BETA DRUGS LIMITED

BDL/PKL/SEC/2024

28th October, 2024

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

Script :-BETA

Dear Sir,

Sub: Corrigendum to the Notice of Extra Ordinary General Meeting of Company Scheduled to be held on Tuesday, November 12, 2024

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated October 19, 2024 wherein the Company has informed about the Extra Ordinary General Meeting ("EGM") of the shareholders of Beta Drugs Limited which is scheduled to be held on Tuesday, **12th November 2024**, at registered office of the company situated at Village Nandpur, Lodhimajra Road, Baddi Distt Solan, H.P - 174101 at 10:30 a.m.

We would like to inform that the Company has circulated a Corrigendum dated October 28th, 2024 to the shareholders of the Company, to amend and/or provide additional details/clarifications with respect to point 1,8,9 &13 of the Explanatory Statement to the EGM Notice under "Item No. 2". The Corrigendum shall form an integral part of the Notice, which has already been circulated to the Members of the Company, and on and from the date hereof, the Notice shall always be read in conjunction with this Corrigendum. Except as detailed in the attached Corrigendum, all other items of the EGM Notice along with Explanatory Statement dated October 19th 2024, shall remain unchanged. The said Corrigendum is also available on the Company's website at i.e., www.betadrugslimited.com

You are kindly requested to take the same on record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com



BETA DRUGS LIMITED

CORRIGENDUM TO THE NOTICE OF THE EXTRA ORDINARY GENERAL MEETING (EGM)

This Corrigendum is being issued in continuation of Extra Ordinary General Meeting (EGM) notice dated 19th October, 2024 scheduled to be held on Tuesday, 12th November, 2024 at 10.30 AM. IST at registered office of the company situated at Village Nandpur, Lodhimajra Road, Baddi Distt Solan, H.P - 174101. The notice of EGM was dispatched to the shareholders of the Company on 19th October, 2024 electronically & by courier in due compliance with the provisions of the Companies Act, 2013, as amended, and the rules made thereunder (the "Companies Act"), read with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India ("SEBI"), to transact the business stated therein.

This Corrigendum to the EGM Notice ("Corrigendum") is issued in respect of the following point 1,8,9 &13 of the Explanatory Statement to the EGM Notice under "Item No. 2", to provide certain clarifications pursuant to the suggestions / comments received from National Stock Exchange of India Limited:-

1. In the explanatory statement "Item No. 2", point 1 should be read as follows:

1. Object of the preferential issue of equity shares:

Subject to applicable law, the Company shall utilize the proceeds from the preferential issue for funding capital investment or expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries) and other general corporate purposes. The Company will use the Subscription Amount for the following purposes:

#	Use of Funds	Estimated Amount (INR cr)	Timeline
1	Capital Expenditure and Capital Investment (Manufacturing/ R&D capabilities)	72	Within 24 months from the date of allotment of CCDs
2	Geographic expansion (Organic/ Inorganic)	20	
3	General Corporate	25	
	Total	117	

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com

The fund requirement and the proposed utilization schedule are based on management estimates, market conditions, business needs and other commercial and technical factors, and the actual deployment of funds at each stage will depend on a number of factors such as financial, market and sectoral conditions, business performance and strategy, and other external factors (such as competitive environment, pandemic and related government requirements, employment and disposable income levels, demographic trends, technological changes, changing customer preferences and increasing regulations or changes in government policies), which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the net proceeds at the discretion of the Board, subject to compliance with applicable laws.

Pending utilization of the proceeds from the Preferential Issue, the Company may invest such proceeds in money/debt market instruments (including mutual funds and liquid funds), deposits in scheduled commercial banks, or any other avenues as permitted under applicable laws.

Further it is confirmed that company will not invest in capital eroding and high risk taking instruments and all other investment shall be done in compliance with the applicable laws.

2. In the explanatory statement “Item No. 2”, point 8 should be read as follows:

8. Identity the Proposed Allottee and the percentage of post preferential issue capital that may be held by them:

To meet the object of the issue, below Proposed Allottee, has shown its intent to subscribe to Equity Shares and CCDs of the Company.

Name of the Proposed Allottees	Category	Pre issue Shareholding		No. of equity shares to be allotted	No. of CCD shares to be allotted	Post issue Shareholding	
		Number	% of shares			Number	% of shares
Healthquad Fund II (a scheme under Healthquad Trust II)	Non-promoter	0	0.00%	70	4,53,623	4,53,693	4.40%
Inti Capital VCC - Inti Capital I	Non-promoter	0	0.00%	30	2,11,691	2,11,721	2.05%
Generational Capital Breakout Fund 1	Non-promoter	14,000	0.15%	0	42,337	56,337	0.55%

3. In the explanatory statement “Item No. 2”, point 9 should be read as follows:

9. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issue capital that may be held by them and change in control, if any, in the issuer consequent to the preferential allotment

Name of the Proposed Allottees	Pre issue Shareholding		Post issue Shareholding		Details of Ultimate Beneficial Owners
	Number	% of shares	Number	% of shares	
Healthquad Fund II (a scheme under Healthquad Trust II)	0	0.0%	4,53,693	4.40%	Charles Antoine Janssen
Inti Capital VCC - Inti Capital I	0	0.0%	2,11,721	2.05%	Raunaq Chamdia
Generational Capital Breakout Fund 1	14,000	0.15%	56,337	0.55%	Satwik Jain

4. In the explanatory statement “Item No. 2”, point 13 should be read as follows:

13. Re-computation of Issue Price:

Since the Company’s equity shares are frequently traded and have been listed on a recognized Stock Exchange for more than 90 trading days prior to the Relevant Date, there is no need for the Company to re-compute the price of equity shares to be issued on preferential basis.

However as per regulation 163 (1) (g) & (h) if it is required to re-compute the price of the specified securities in terms of the provision of these regulations, same will be re-computed and if the amount payable on account of the re-computation of price is not paid within the time stipulated in these regulations, the specified securities shall continue to be locked- in till the time such amount is paid by the allottees.

Members are requested to kindly take note of the aforesaid amendments in the notice and the corresponding corrections before casting their votes.

The Corrigendum to the EGM Notice shall form an integral part of the EGM Notice which has already been circulated to the Members of Company and on and from the date hereof, the EGM Notice shall always be read in conjunction with this Corrigendum. This Corrigendum will also be made available on website of the stock exchange i.e., NSE i.e., www.nseindia.com and on the website of the Company on www.betadrugslimited.com. All other contents of the EGM Notice, save and except as modified or supplemented by the Corrigendum, shall remain unchanged.

By Order of the Directors

**Place: Baddi
Date: 28.10.2024**

**sd/-
Ms. Rajni Brar
Company Secretary**